A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.
Created by ecenci@menarini.it on 9/7/2020 8:12:31 AM


September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany


A.Menarini Diagnostics and Bioactiva GmbH announced today that they have signed an Agreement under which A. Menarini Diagnostics will be the exclusive Distributor for the Lioferon®TB/LTBI ELISA Assay in Italy, Spain, Benelux, UK, France, Austria, Sweden, Finland, Norway and Denmark.

Fabio Piazzalunga, Menarini Diagnostics Global General Manager commented: “This agreement represents a great opportunity for our Company to improve the diagnosis of both TB and LTBI in order to set-up new screening tests that can be used for public health. Tuberculosis remains one of the three top causes of mortality from infectious diseases worldwide. We are strongly focused in offering an efficient and affordable solution for the prevention of new infections and their progression to TB disease to achieve the End TB Strategy targets set by WHO (-80%)”.

The LIOFeron®TB/LTBI is a cytokine release assay for quantitative determination of Interferon Gamma (IFN-γ) produced by human blood cells stimulated with Mycobacterium tuberculosis (MTB) antigens.

The kit distributed by A.Menarini Diagnostics has shown very good sensitivity and specificity performances in diagnosing active TB patients (90% and 98% respectively) and excellent sensitivity and specificity performances in diagnosing LTBI subjects (94% and 97%)[1].

Please visit our website https://www.menarinidiagnostics.com/en-us/Home/Laboratory-products/Infectious-Diseases/LIOFeronTB-LTBI/Features or contact us for further information. 

 

A. Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded in 1886. Today it is present in 140 countries throughout the world, it counts more than 17,000 employees and has a 2019 turnover of € 3.793 billion.

A. Menarini Diagnostics, the human touch of technology, is fully committed to develop high tech diagnostics instruments and reagents to improve the quality of life of patients, providing healthcare professionals the best possible solutions to diagnostics needs. For further information, please visit www.menarinidiagnostics.com

A.Menarini Diagnostics S.r.l. Via dei Sette Santi, 3 Florence Italy

 


The company bioactiva diagnostica GmbH was founded in 2001 by the biologist Adnan Dawoud in Frankfurt a.M. In 2004 the company relocated to Bad Homburg. The defined goal of bioactiva diagnostica GmbH is to offer one-stop high-quality products in the areas of in vitro diagnostics, medical technology, and laboratory equipment. Our products stand out with their innovation and simultaneously good value

Our long experience guarantees smooth and fast delivery. Client preference is the top priority. Due to our flexible structures, we can virtually fulfil each and every client’s request. Our market position is enhanced by exclusively offering selected products.

 

[1] LIOFeronTB/LTBI: A novel and reliable test for LTBI and tuberculosis, Chiara Della Bellaa, Michele Spiniccia, Heba F. Mustafa Alnwaisria, Filippo Bartalesia, Simona Tapinassia, Jessica Mencarinia, Marisa Benagianoa, Alessia Grassia, Sofia D’Eliosc, Arianna Troiloa, Arailym Abilbayevad, Dinara Kuashovad, Elmira Bitanovad, Anel Tarabayevad, Eduard Arkadievich Shuraleve, Alessandro Bartolonia, Mario Milco D’Elios